default author photo

Guillermo Garcia-Manero

University of Texas at Houston - Department of Leukemia

SCHOLARLY PAPERS

4

DOWNLOADS

403

TOTAL CITATIONS

0

Scholarly Papers (4)

1.

Ponatinib and Blinatumomab for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Phase 2 Trial

Number of pages: 28 Posted: 27 Apr 2022
University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Leukemia, The University of Texas MD Anderson Cancer Center - Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia and University of Texas at Houston - Department of Leukemia
Downloads 222 (343,660)

Abstract:

Loading...

blinatumomab, ponatinib, Philadelphia Chromosome, bcr-abl1, ALL

2.

Combination of Oral Decitabine/Cedazuridine and Venetoclax in Patients with Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Number of pages: 30 Posted: 21 Sep 2023
University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Miami - Sylvester Comprehensive Cancer Center, University of Texas at Houston - Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Hematopathology, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia and University of Texas at Houston - Department of Leukemia
Downloads 84 (777,583)

Abstract:

Loading...

myelodysplastic syndromes, MDS, oral decitabine, venetoclax, chronic myelomonocytic leukemia, CMML

3.

Results of Salvage Therapy with Mini-Hyper-CVD and Inotuzumab Ozogamicin with or Without Blinatumomab in Pre-B Acute Lymphoblastic Leukemia

Number of pages: 45 Posted: 06 Dec 2022
University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Hematopathology, University of Texas at Houston - Department of Hematopathology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Pharmacy, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of California, Irvine - Chao Family Comprehensive Cancer Center, University of Texas at Houston - Department of Leukemia and University of Texas at Houston - Department of Leukemia
Downloads 73 (860,052)

Abstract:

Loading...

Philadelphia-negative ALL, inotuzumab, blinatumomab, chemo-immunotherapy, salvage, outcome

4.

Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia

Number of pages: 37 Posted: 27 Apr 2026
University of Texas at Houston - Department of Leukemia, University of Texas at Houston - MD Anderson Cancer Center, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, affiliation not provided to SSRN, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, affiliation not provided to SSRN, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, affiliation not provided to SSRN, University of Texas at Houston - Department of Leukemia, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Texas at Houston - Department of Biostatistics, affiliation not provided to SSRN, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Leukemia and University of Texas at Houston - Department of Leukemia
Downloads 24 (1,411,822)

Abstract:

Loading...

Area deprivation index, racial/ethnic disparity, clinical trials, stem cell transplant